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Introduction: Comprehensive medication management (CMM) is a patient care process provided by 
clinical pharmacists in primary care settings that ensures optimal use of medications with timely follow-
up. Despite widespread evidence that shows CMM improves clinical and medication-related outcomes, 
pharmacist CMM services often fail to be adopted into U.S. primary care settings.  
 
Objective: This study presents a conceptual framework linking outcomes of pharmacist-delivered CMM 
services in primary care settings to financial benefits for both primary care practices investing and 
implementing CMM and health plans providing coverage of CMM services. 
 
Methods: A narrative literature review was performed in PubMed and the gray literature to identify 
financing opportunities that justify the coverage of CMM by third party health plan administrators or the 
implementation of CMM by primary care practices. Financing elements that could be impacted by 
pharmacist-led CMM outcomes, namely higher achievement of medication-related quality measures 
and reduction of total costs of care, were recorded and utilized to develop the conceptual framework. 
 
Results: The framework suggests that CMM may provide economic benefits to health plans and care 
practices by (1) increasing market competitiveness through higher quality ratings, accreditation 
recognition, lower premiums and plan bids, and increased patient satisfaction; and (2) increasing 
revenue through quality bonus payments, shared savings agreements, and fee-for-service 
reimbursement.  
 
Conclusions: The alignment of economic benefits that can be realized through CMM advances a strong 
value proposition for greater adoption of CMM in the United States’ primary care system. Future 
application of this study’s conceptual framework could include use as an advocacy tool amongst 





The misuse, underuse, and overuse of medications is one of the largest preventable factors 
contributing to lower health care quality in the United States. While prescription drug spending in the 
U.S. is estimated to be $330 billion of the $3.3 trillion in total health expenditures, costs resulting from 
non-optimized medication therapy have been estimated to exceed $500 billion, implying that for every 
dollar spent on medications an additional dollar is needed to address inappropriate medication use.1,2 
One solution for reducing unnecessary medication-related spending is comprehensive medication 
management (CMM), a clinical service delivered by pharmacists using an integrated care team 
approach. The CMM patient care process ensures that each patient’s medications are evaluated to 
determine appropriateness, effectiveness, safety, adherence, and accessibility resulting in an 
individualized care plan with timely follow-up.3  
Pharmacist-led CMM has consistently demonstrated positive clinical outcomes most often 
achieved through identification and resolution of medication therapy problems (MTPs). On average, 
studies of CMM services have shown identification and resolution of 4.5 MTPs per patient with the most 
frequent type of MTP identified including need for additional medication therapy or suboptimal dosing 
of an existing therapy.4–13 Examples of relevant CMM interventions include addition of indicated statins 
or asthma inhaler therapy, increasing beta blocker doses for heart failure patients, or discontinuing high 
risk medications in elderly patients.  
In terms of diabetes management, studies have shown that CMM leads to significant reductions 
in hemoglobin A1c compared to control arms with estimated treatment differences ranging from -0.4% 
to -1.7%.14–18 Moreover, several studies have demonstrated CMM’s positive impact on all-or-none 
diabetes composite scores that involve achievement of several important treatment goals including 
smoking cessation, daily aspirin use, and meeting A1c, low density lipoprotein (LDL), and blood pressure 
goals.5–7,15 Some studies of well-adopted CMM services have even demonstrated a positive impact on 
lowering patient total cost of care by decreasing hospitalizations and other acute care utilization.8,13 
Despite widespread evidence that shows CMM improves clinical and medication-related 
outcomes, pharmacist CMM services fail to be consistently adopted into U.S. primary care settings.19–
21,22 CMM services are often funded through unsustainable means such as temporary grants,11,12,16,23 
pilot programs,8 or limited fee-for-service billing reimbursement.5,6,9,10  
Fortunately, the current healthcare policy landscape and value-based directive in the U.S. 
presents a favorable environment for the economic justification of pharmacist CMM services. In the new 
age of emphasis on value and the partial transfer of risk from payers to delivery systems, CMM has the 
potential to be financially viable.24,25 This study presents a theoretical framework to conceptualize how 
CMM-driven outcomes can financially benefit third party health plans and primary care delivery systems 
deliberating about whether to reimburse for or implement pharmacist CMM services.     
 
METHODS 
A critical review of the literature was performed to discern financing opportunities that justify 
the coverage of CMM by third party health plan administrators or the implementation of CMM by 
primary care practices.  
In order to develop the narrative framework, a paradigm was applied that presumes pharmacist 
CMM services result in lower total costs of care through decreased acute care utilization and higher 
achievement of medication-related quality measures.  Thus, financing elements that could be positively 
impacted by either lower total costs of care or higher achievement of quality measures were assumed to 
contribute to the economic justification for CMM. This paradigm is supported by the literature and 
continues to be evaluated as the value of clinical pharmacy services gains national attention. 
The literature review focused on financing elements between U.S. healthcare financers 
(individuals, employers, and government), third party health plan administrators, and primary care 
delivery systems. Specifically, the scope of the framework was limited to health insurance through 
Medicare, Medicaid, fully or self-insured employers, and the exchange marketplace as these make up 
the bulk of health financing in the United States.26–28 Financing of primary care practices inclusive of 
physicians organized into Accountable Care Organizations (ACOs) or Patient-Centered Medical Homes 
(PCMHs) was also evaluated.  
Literature searches were conducted in PubMed and the gray literature through use of key terms 
and synonyms that reflected financing models between the chosen stakeholders (e.g. Medicare 
Advantage financing, ACO Medicare financing, etc). Titles and abstracts were scanned to identify articles 
that discussed relevant revenue models. For financing elements where more detailed information was 
available (e.g. Medicare Advantage Stars quality bonus payments), secondary searches were performed 
to understand contract specifics such as relevant quality metrics or risk-adjustment factors. Financing 





CMM Value Proposition within the U.S. Healthcare System: A Conceptual Framework 
 
This framework presents the economic value proposition for CMM in primary care settings (Figure 1). 
Within the framework are three key categories of stakeholders, including financers of healthcare (i.e. 
employers, individuals, and the government), third party health plans that facilitate contracts and health 
benefits on behalf of financers, and primary care practices where CMM services may be implemented. 
Individuals traditionally receive health insurance through their employer, direct purchase facilitated by 
an exchange, or eligibility for government programs. Employers may provide healthcare benefits to their 
employees by contracting with a third-party payer (fully-insured) or by contracting directly with 
healthcare systems (self-insured).26 Similarly, Medicare and Medicaid programs may be facilitated 
through contracts with third party health plans (i.e. Medicare Part C and Medicaid managed care) or 
direct contracts with healthcare delivery systems (i.e. traditional Medicare and non-managed 
Medicaid).27,28  
The following sections will narrate how clinical and economic outcomes from CMM services can 
benefit third party health plans and primary care delivery systems through various mechanisms 
elucidated from the literature review.  
 
CMM From a Third-Party Health Plan Perspective 
 
The primary lines of business for third party health plans include Medicare Advantage (MA) 
plans, state Medicaid managed care plans, and commercial plan contracts purchased by employers or 
individuals. CMM has the opportunity to benefit all lines of business through the following mechanisms: 
(1) increased market competitiveness, (2) achievement of quality bonus payments, and (3) increased 
revenue from capitated shared savings contracts.  
Coverage of CMM services may increase health plan market competitiveness by lowering health 
plan total medical costs, thus allowing plans to lower their bids within request for proposals (RFPs) to 
Medicare and Medicaid or offer lower premiums within the commercial market.29 In addition, CMM has 
the potential to increase market competitiveness by improving plan ratings. In the commercial market, 
the National Committee for Quality Assurance (NCQA) accredits health plans and assigns plan quality 
ratings, both of which are essential for winning contracts from large employers looking to provide a 
high-quality benefit package to their employees.30,31 NCQA ratings and accreditation are based on 
achievement of Healthcare Effectiveness Data Information Set (HEDIS) quality measures including 
process (e.g. statin therapy in cardiovascular disease), outcome (e.g. controlled A1c, reduction in 
hospitalizations), and patient experience measures.31,32 Over 30% of HEDIS quality measures are related 
to medications or medication-related treatment outcomes that are either a result of CMM MTP 
resolution (e.g. addition of an indicated statin) or that serve as a goal of CMM care (e.g. controlled blood 
pressure).32 Similarly, in the Medicare market, Stars Ratings serve as a way to rank a high-quality plan. Of 
the 48 Stars Measures for 2018, 15 (31%) are either related to medication management (e.g. diabetes 
medication adherence, achievement of blood pressure control) or outcomes positively influenced by 
CMM such as hospital readmissions (see Table 1).33 Of note, 66% of Medicare Advantage enrollees in 
2017 were enrolled in a plan with a Star Rating of 4 or more Stars on the 5-star scale, indicating the 
impact of high quality ranking on member enrollment.28   
CMM can directly influence plan revenue through achievement of quality bonus payments. In 
the Medicare Advantage program, a quality bonus incentive payment of 5% is given to those plans who 
achieve a Star rating of 4 or higher.34 Quality bonus payments are also present in some state Medicaid 
programs such as New York, where plans may receive bonuses upon high quality measure 
performance.35  
Lastly, through lowering cost of care and higher achievement of quality measures, CMM can 
benefit plans engaged in capitated shared savings contracts such as the Medicare Advantage payment 
system. In the MA market, plans submit bids to CMS that estimate the cost to cover an average 
beneficiary. Plans who submit bids lower than a CMS calculated benchmark rate have the opportunity to 
gain a portion of the “savings” (difference between the benchmark and plan bid).29 Lowering the total 
cost of care of a plan population through mediation management can help plans submit lower bids and 
recoup a larger magnitude of savings. In addition, the proportion of savings that is repaid to Medicare 
Advantage plans, also known as the MA rebate, is dictated by Star Ratings which may be impacted by 
CMM. Plans with 4.5 stars or higher receive a 70% rebate, whereas plans with 3 stars or lower only 
receive a 50% rebate.34  
 
CMM From a Primary Care Practice Perspective 
 
Primary care practices may be primarily funded through traditional FFS reimbursement or organized 
into models where care coordination, quality, and cost-effectiveness are emphasized such as patient-
centered medical homes (PCMHs) or accountable care organizations (ACOs). Depending on practice 
structure, CMM has the opportunity to benefit primary care practices through (1) increased market 
competitiveness, (2) traditional FFS payments, (3) quality bonus payments, and (4) shared savings.  
Integrating CMM into primary care practices can increase market competitiveness with consumers 
and health plans. Consumers have demonstrated high patient satisfaction with CMM services and 
increased confidence in managing their disease.4,5,10,14 Practices may use patient anecdotes as a 
marketing tactic to increase volume. In addition, CMM can increase contract negotiating power with 
health plans. First, CMM can help improve quality metrics, patient satisfaction, and acute care utilization 
which provide important data that can be leveraged in insurer negotiations. Second, CMM 
implementation can help with requirements for ACO or medical home accreditation. For example, the 
NCQA PCMH Recognition process requires team-based care, delivery of guideline-directed care, 
medication education and counseling, establishment of person-centered care plans for high risk 
patients, and other requirements that can be addressed by the CMM care process.36 Not only does 
recognition as a medical home or ACO improve practice bargaining power and market competitiveness 
with health plans, but it can also increase practice revenue in the form of additional care management 
fees, quality bonuses, or shared savings.37,38 
Pharmacist-delivered CMM services can also generate direct revenue from traditional FFS billing. 
Although FFS reimbursement is often insufficient to cover all costs associated with CMM, it can provide 
consistent supplemental revenue in addition to the other economic benefits discussed in this 
framework. Certain states such as Minnesota have recognized the value of pharmacist CMM services 
and have created a FFS reimbursement structure to recognize CMM care delivery.6 However, for the 
majority of practice settings, FFS billing for CMM can either be achieved directly though CPT code 99211 
($20-$30) or through physician “incident-to” billing for a variety of scenarios where reimbursement may 
range from $40 to $226 (see Table 2).39 These may include transitional care management (CPT 99495, 
99496), annual wellness visits (G0438, G0439), or newer chronic care management codes (CPT 99490).40 
Practices have the opportunity to be innovative with the CMM care process in order to receive maximal 
reimbursement. Two real-world examples of this include incorporating Annual Wellness Visits into the 
CMM process29 and MD/PharmD co-appointments that allow for physicians to see more patients daily 
and bill at a higher complexity.41  
Practices can also achieve direct revenue through quality bonus incentive payments with 
commercial and government payers through the Merit-Based Incentive Payment System (MIPS) and 
pay-for-performance (P4P) models.42,43 Due to the recent Medicare physician reimbursement overhaul 
known as the Medicare Access and CHIP Reauthorization Act of 2015, primary care physicians will be 
engaged in upside-downside risk adjustments that can affect up to 9% of their Medicare 
reimbursement.43 These adjustments will be based on MIPS composite scores that incentivize quality, 
efficient resource utilization, practice quality improvement activities, and advancement of health 
information technology. Sixty percent of the MIPS score is made up of achievement of quality measures 
and resource utilization (i.e. cost of medical claims), which may be positively impacted by CMM 
interventions.43 Several MIPS quality measures are related to chronic medication management such as 
evidence-based therapy for heart failure, improvement in blood pressure, and optimal asthma control.44 
In addition to Medicare’s MIPS program, pay-for-performance models are another form of quality bonus 
payments. P4P arrangements vary widely and are ubiquitous across Medicare, Medicaid, and 
commercial contracts.42 P4P may be based on achievement of quality measures such as following 
guideline-based therapy or based on lowering acute care utilization, both of which can be supported by 
the CMM care model.  
Lastly, through lowering acute care utilization, CMM has the potential to increase shared savings for 
practice settings where capitation is the primary reimbursement model such as in ACOs. As health 
systems take on more risk for attributed patient panels, investment in services that aim to manage 
chronic disease and prevent avoidable complications will be integral for driving revenue.45  
   
DISCUSSION 
This study presents a novel conceptual framework describing the economic value proposition for 
CMM in the U.S. healthcare system from a dual stakeholder perspective. The framework demonstrates 
aligned economic justification for CMM by both primary care practices investing and implementing 
CMM and health plans providing coverage of CMM services. Namely – depending on the patient mix, 
health plans and care practices may increase market competitiveness and increase revenue by adopting 
CMM.  
Health plans and care practices alike can increase their market competitiveness through CMM 
services. Specifically, health plans have the opportunity to increase their competitiveness with 
Medicare, patients, and even employer groups through achieving lower RFP bids or premiums and 
achieving higher quality metrics that allow for higher plan ratings and NCQA accreditation. Similarly, 
care practices have the opportunity to remain competitive with contracted plans and patients. CMM 
services give care practices the marketing opportunity to tout high patient engagement, exceptional 
follow up, and disease management education to complex patients who often feel overwhelmed by the 
system. In addition, through greater achievement of quality metrics and adoption of the CMM care 
model, care practices may increase their negotiating power with contracted health plans.   
 CMM services can also directly and indirectly drive revenue for health plans and care practices 
through quality bonus payments, shared savings agreements, and fee-for-service reimbursement. 
Ultimately, the focal point of these revenue opportunities for health plans and care practices alike is 
centered around achievement of value-based quality measures as well as lowering total medical costs. 
Given that the sustainability of CMM implementation is based on these outcomes, practices and health 
plans should carefully consider quality measures they are held accountable for and create infrastructure 
to help improve those outcomes. Health plans should focus on using analytics to identify quality 
opportunities, improve communication with providers and care practices to address those gaps, and 
create practice-level incentives for quality measures that can help fund and sustain CMM services. 
Similarly, care practices should also invest in analytics to identify quality opportunities, educate 
providers and care team members on the importance of quality-based initiatives, and ensure their CMM 
care process is nimble in order to continuously address different gaps in care.  
 There are a few limitations to this study. First, publicly available information regarding 
commercial contract data between employers and health plans as well as health plans and care 
practices is very limited. Although the literature suggests that there is an increasing commercial focus on 
value and quality measures, the magnitude and specifics of this change remains unknown. Future 
studies could attempt to address this gap in the literature through surveys and focus groups of 
commercial payers.  
Second, this framework is dependent on the stated paradigm that CMM services result in lower 
total costs of care and higher achievement of medication-related quality measures. There is a growing 
body of literature that supports this paradigm; however, it remains difficult to ascertain macro level 
changes such as an improvement in a plan’s Star rating to a single intervention. In order to combat this, 
care practices should remain committed to tracking interventions and outcomes to continue generating 
evidence for CMM services. One innovation that may help with tracking outcomes is the introduction of 
SNOMED CT codes, a new coding system to record care interventions in electronic health record (EHR) 
systems. Adoption and consistent use of SNOMED CT codes as a way to track and monitor interventions 
made by pharmacists can present an opportunity to make a more convincing value argument for 
CMM.46 
Finally, this framework is qualitative in nature, and thus the magnitude of the economic benefits of 
CMM are not evaluated here. Future studies could work to develop a flexible model that allows health 
plans and care practices to input their population mix (e.g. Medicare, Medicaid, commercial) and 
analyze how incorporation of CMM services could positively influence their bottom line.  
Future application of this study’s conceptual framework could include use as an advocacy tool 
amongst pharmacy associations or as a tool for individuals seeking buy-in for CMM services. Examples of 
this may include primary care practices looking to convince health plans to reimburse for CMM within 
their contracts or pharmacists looking to convince health system administrators to implement CMM 
services within additional clinics. In both of these scenarios, this conceptual framework can serve as a 




This study presents a novel framework for justifying the adoption of pharmacist comprehensive 
medication management services in the United States. By improving healthcare quality measures and 
decreasing acute complications of chronic disease management, CMM can increase health plan and 
primary care practice market competitiveness and increase revenue. The broad alignment of benefits 
that can be realized across the healthcare system advances a strong value proposition for greater 
adoption of CMM in the United States’ primary care system.  
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Figure 1. Conceptual framework describing the economic value proposition for CMM within the U.S. healthcare system.  
 
 
ACO = accountable care organization, CPC+ = comprehensive primary care , FFS = fee for service, MA = Medicare Advantage, MIPS = Merit-Based Incentive Payment System, 
NCQA = National Committee for Quality Assurance, P4P = pay for performance, PCMH, = patient centered medical home, TPA = third party administrator.  
Table 1. 2018 Medicare STAR measures influenced by pharmacist CMM services.  
Annual flu vaccine Medication Reconciliation Post-Discharge 
Care for Older Adults – Medication Review Plan All-Cause Readmissions 
Osteoporosis Management in Women who had a Fracture Medication Adherence for Diabetes Medications 
Diabetes Care - Blood Sugar Controlled Medication Adherence for Hypertension (RAS antagonists) 
Controlling Blood Pressure Medication Adherence for Cholesterol (Statins) 
Rheumatoid Arthritis Management MTM Program Completion Rate for CMR 
Reducing the Risk of Falling Getting Needed Prescription Drugs 
Improving Bladder Control  
 
 
Table 2. Billing codes related to CMM services.  
HCPCS Code Code Description 2018 Reimbursement 
Fee Schedule 
CPT 99211 Evaluation and management service office or 
other outpatient visit that may not require the 
presence of a physician 
$22 
CPT 99490 Chronic care management service - 20 minutes $42 
CPT 99495 Transitional care management - 14-day discharge $167 
CPT 99456 Transitional care management - 7-day discharge $236 
G0438 Annual Wellness Visit - initial visit $175 
G0439 Annual Wellness Visit - subsequent visit $119 
 
 
